Pieter-Jan Van Bockstal

Pieter-Jan Van Bockstal

Auto-generated profile, based on publicly available information

Pieter-Jan Van Bockstal

Laboratory of Pharmaceutical Process Analytical Technology, Department of Pharmaceutical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGEdward Geeurickx
Edward Geeurickx
JTJoeri Tulkens
Joeri Tulkens
BDBert Dhondt
Bert Dhondt
JDJan Van Deun
Jan Van Deun
LLLien Lippens
Lien Lippens
AHAn Hendrix
An Hendrix
Recent years have seen an increase of extracellular vesicle (EV) research geared towards biological understanding, diagnostics and therapy. However, EV data interpretation remains challenging owing to complexity of biofluids and technical variation introduced during sample preparation and analysis. To understand and mitigate these limitations, we generated trackable recombinant EV (rEV) as a biological reference material. Employing complementary characterization methods, we demonstrate that rEV are stable and bear physical and biochemical traits characteristic of sample EV. Furthermore, rEV can be quantified using fluorescence-, RNA- and protein-based technologies available in routine laboratories. Spiking rEV in biofluids allows recovery efficiencies of commonly implemented EV separation methods to be identified, intra-method and inter-user variability induced by sample handling to be defined, and to normalize and improve sensitivity of EV enumerations. We anticipate that rEV will aid EV-based sample preparation and analysis, data normalization, method development and instrument calibration in various research and biomedical applications.

1 December 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LML. De Meyer
L. De Meyer
PBP.-J. Van Bockstal
P.-J. Van Bockstal
JCJ. Corver
J. Corver
CVC. Vervaet
C. Vervaet
JRJ.P. Remon
J.P. Remon
TBT. De Beer
T. De Beer

1 June 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GVG. Verstraete
G. Verstraete
JRJ. Van Renterghem
J. Van Renterghem
PBP.J. Van Bockstal
P.J. Van Bockstal
SKS. Kasmi
S. Kasmi
BGB.G. De Geest
B.G. De Geest
CVChris Vervaet
Chris Vervaet

8 January 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TDTu Van Duong
Tu Van Duong
DLDavid Lüdeker
David Lüdeker
PBPieter-Jan Van Bockstal
Pieter-Jan Van Bockstal
TBThomas De Beer
Thomas De Beer
JHJan Van Humbeeck
Jan Van Humbeeck
Guy Van den MooterGuy Van den Mooter
Guy Van den Mooter

1 June 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
IOIrene Oddone
Irene Oddone
PBPieter-Jan Van Bockstal
Pieter-Jan Van Bockstal
TBThomas De Beer
Thomas De Beer
Roberto PisanoRoberto Pisano
Roberto Pisano

1 June 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SMSéverine Thérèse F.C. Mortier
Séverine Thérèse F.C. Mortier
PBPieter-Jan Van Bockstal
Pieter-Jan Van Bockstal
JCJos Corver
Jos Corver
Ingmar NopensIngmar Nopens
Ingmar Nopens
Krist V. GernaeyKrist V. Gernaey
Krist V. Gernaey
Thomas De BeerThomas De Beer
Thomas De Beer